Friday, February 12, 2016 11:29:58 AM
Movers and Shakers in Biotech: One Up, One Down - article discusses FibroGen
http://marketexclusive.com/2872-2/2872/
http://marketexclusive.com/2872-2/2872/
Recent FGEN News
- Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 • GlobeNewswire Inc. • 02/23/2026 10:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/07/2026 09:15:12 PM
- FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum • GlobeNewswire Inc. • 01/07/2026 12:30:00 PM
- FibroGen Shares Advance After Roxadustat Earns Orphan Drug Status • IH Market News • 12/15/2025 01:32:58 PM
- Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration • GlobeNewswire Inc. • 12/15/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:11:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:10:11 PM
- FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit • GlobeNewswire Inc. • 12/02/2025 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2025 09:42:52 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2025 11:41:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/10/2025 09:11:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 09:05:28 PM
- FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/10/2025 09:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2025 09:11:47 PM
- FibroGen to Report Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/03/2025 09:02:00 PM
- FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer • GlobeNewswire Inc. • 09/24/2025 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2025 11:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2025 09:04:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/02/2025 12:00:29 PM
- FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million • GlobeNewswire Inc. • 09/02/2025 11:00:00 AM
- FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2025 08:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/18/2025 12:45:29 PM
- FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation • GlobeNewswire Inc. • 08/18/2025 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2025 08:10:27 PM
